Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor
- PMID: 10383128
Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors are members of the tumor necrosis factor superfamily. TRAIL selectively kills cancer cells but not normal cells. We report here the cloning of the mouse homologue of the TRAIL receptor KILLER/DR5 (MK). The cDNA of MK is 1146 bp in length and encodes a protein of 381 amino acids. MK contains an extracellular cysteine-rich domain, a transmembrane domain, and a cytoplasmic death-domain characteristic of Fas, tumor necrosis factor, and human TRAIL receptors. MK is highly homologous and binds TRAIL with similar affinity as human DR4 and KILLER/DR5. MK induces apoptosis in mouse and human cells and inhibits colony growth of NIH3T3 cells. Expression of MK is p53-dependent and up-regulated by tumor suppressor p53 and by DNA damaging agents in mouse cells undergoing apoptosis. This is the first report describing a mouse TRAIL receptor gene and also demonstrating that the p53-dependent regulation of KILLER/DR5-mediated apoptosis is conserved between human and mouse.
Similar articles
-
Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.Cancer Res. 2003 Mar 1;63(5):1059-66. Cancer Res. 2003. PMID: 12615723
-
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.Cancer Res. 2001 Mar 15;61(6):2704-12. Cancer Res. 2001. PMID: 11289151
-
Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.Cancer Res. 2000 Aug 1;60(15):4122-9. Cancer Res. 2000. PMID: 10945619
-
Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Cancer Gene Ther. 2005 Mar;12(3):228-37. doi: 10.1038/sj.cgt.7700792. Cancer Gene Ther. 2005. PMID: 15550937 Review.
-
The TNF ligand superfamily and its relevance for human diseases.Cytokines Mol Ther. 1995 Jun;1(2):75-105. Cytokines Mol Ther. 1995. PMID: 9384666 Review.
Cited by
-
Molecular mechanisms of neonatal brain injury.Neurol Res Int. 2012;2012:506320. doi: 10.1155/2012/506320. Epub 2012 Jan 26. Neurol Res Int. 2012. PMID: 22363841 Free PMC article.
-
Membrane trafficking of death receptors: implications on signalling.Int J Mol Sci. 2013 Jul 11;14(7):14475-503. doi: 10.3390/ijms140714475. Int J Mol Sci. 2013. PMID: 23852022 Free PMC article. Review.
-
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.Cell Death Differ. 2012 Dec;19(12):2003-14. doi: 10.1038/cdd.2012.90. Epub 2012 Jul 20. Cell Death Differ. 2012. PMID: 22814620 Free PMC article.
-
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Am J Cancer Res. 2012;2(1):45-64. Epub 2011 Oct 9. Am J Cancer Res. 2012. PMID: 22206045 Free PMC article.
-
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.J Clin Invest. 2008 Jan;118(1):100-10. doi: 10.1172/JCI33061. J Clin Invest. 2008. PMID: 18079967 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous